

21

Dimethyl

2-[2-[2-(6-hydroxy-2,5,7,8-tetramethylchroman)ethoxy]methyl]-6-methyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate

Following the procedure of example 7, the title compound is prepared by substituting 2-nitrobenzaldehyde for 3-nitrobenzaldehyde.


The following example is provided to further illustrate the pharmaceutical compositions of the present invention, particularly compositions intended for topical application to the eye. In this example, the term "Compound" is intended to represent any of the compounds of formula (I) and formula (II) above.

EXAMPLE 9


Ingredient	Amount (wt. %)	Purpose
Compound (free base)	1.0	Active ingredient
Polyvinyl alcohol, USP	1.4	Excipient
Monobasic sodium phosphate (Monohydrate), USP	0.05	Buffering agent
Dibasic Sodium Phosphate (Anhydrous), USP	0.15	Buffering agent
Sodium chloride, USP	0.5	Tonicity agent
Disodium EDTA (Edetate disodium), USP	0.01	Preservative
Polysorbate 80, NF	0.05	Surfactant
Benzalkonium chloride solution, NF	0.01 + 5 excess	Preservative
Sodium hydroxide, NF	q.s.	pH adjustment
Hydrochloric acid, NF	q.s.	pH adjustment
Water for injection, USP	q.s.	Vehicle

What is claimed is:

1. A compound of the formula:




or







wherein;

A is an antioxidant selected from the group consisting of:



22

-continued



R is C₁ to C₆ alkyl;

n is a whole number of from 1 to 6;


m is a whole number of from 1 to 6;

Z is O or NH;

Y, if present, is O or S(O)_{n'}, wherein n' is 0, 1 or 2; and

B is:

(I)



45


wherein:

R₁ and R₂ are the same or different and are selected from H, I, Br, Cl, F, CF₃, CN, NO₂ and S(O)_{n'}.


(II)

2. A compound according to claim 1, wherein the antioxidant is selected from the group consisting of:

55



60



65

and